Skip to main content

EQRx, Inc. (EQRXW)

New York Stock Exchange Healthcare BiotechnologyView data quality →
55.3Fair

ValueMarkers Composite Index

Top 55%#20,248 of 44,707

DCF data not available

Piotroski
3/9
Weak
Beneish
-
Altman
10.16
Safe
DCF Value
-
N/A
ROIC
30.8%
Strong
P/E
5.4
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

EQRx, Inc. (EQRXW) — VMCI valuation read

The headline on EQRx, Inc. (EQRXW) is a 55/100 VMCI score, set against a Healthcare sector median of 50. That 5-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

EQRXW insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** EQRXW trades at 17.0x earnings, 6% below the Healthcare median of 18.0x sets the value side. ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of -1.6x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on EQRXW.

EQRXW fell 0.3% over the trailing 7 days, with a -11.3% read on a 30-day basis.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.

CEO: Alexis A. Borisy A.M.216 employeesUSwww.eqrx.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in EQRXW’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.